Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a consensus analyst rating of Buy, based on 14 analysts covering the stock. Of those, 12 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for CRBP is $43.33, representing a +333.3% upside from the current price of $10. Price targets range from a low of $39.00 to a high of $51.00.
